UNASSIGNED: 1540 Background: Through the use of @entity900 -based combination chemotherapy and radiotherapy, outcomes have improved for @entity1 with @entity2971 . An appropriate therapy for recurrent @entity2971 , however, remains to be established. The present feasibility study investigates the @entity137 and activity of a @entity136 / @entity1205 combination in @entity1 with multiply relapsed germ cell @entity5 . METHODS: @entity136 was administered at a dose of 1000 mg/m(2) over 30 minutes on days 1, 8 followed by @entity1205 (1 h-infusion) at a dose of 60 mg/m(2) on day 8, with courses repeated every 21 days. RESULTS: From 9/00 to 9/01 5 @entity1 with a median age of 15 [13-32] years were enrolled. @entity1 had been pretreated with a median of 9 [3-16] @entity3908 -containing cycles and 1 @entity1 had previously failed high-dose chemotherapy with PBSCT. All @entity1 were considered @entity900 -refractory. Median number of applied cycles was 2 [2-4]. All @entity1 achieved a radiological partial response with a @entity5 marker normalization resulting in an objective response rate of 100%. However, the remissions after chemotherapy alone were not durable. Three of the 5 @entity1 received an additional low-dose of irradiation following the chemotherapy. Median progression-free interval was 26 [7-39+] months with 2 @entity1 remaining without disease progression for more than 30 months. @entity137 was generally acceptable: CTC grade III/IV @entity1398 of short duration occurred in all @entity1 . No case of grade III/IV non-hematological adverse effect was observed. CONCLUSIONS: The combination of @entity136 / @entity1205 is feasible and associated with an acceptable @entity137 in @entity1 with multiply relapsed and @entity900 -refractory germ cell @entity5 . It exhibits a significant activity with responses observed in all @entity1 . No significant financial relationships to disclose.

Combination chemotherapy with @entity136 and XXXX for recurrent @entity2971 in the central nervous system.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Toxicity'] @entity3908 :: ('CHEBI:33364', 'Chemical') :: ['platin'] @entity2971 :: ('MESH:D009373', 'Disease') :: ['intracranial germ cell tumor', 'germ cell tumors'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['Gemcitabine', 'gemcitabine']
@entity1205 :: (MESH:C067311,Chemical) :: ['docetaxel']
